CBG Threshold for Short-Acting Insulin in 80-Year-Old Patients
For elderly patients aged 80 years, administer short-acting insulin when premeal capillary blood glucose exceeds 250 mg/dL (13.9 mmol/L), giving 2 units, or when glucose exceeds 350 mg/dL (19.4 mmol/L), giving 4 units. 1
Guideline-Based Thresholds
The 2025 American Diabetes Association Standards of Care for Older Adults provides explicit thresholds for sliding scale insulin administration 1:
- >250 mg/dL (>13.9 mmol/L): Give 2 units of short- or rapid-acting insulin
- >350 mg/dL (>19.4 mmol/L): Give 4 units of short- or rapid-acting insulin
These thresholds are specifically designed for older adults and should be applied as a simplified sliding scale while adjusting prandial insulin regimens. The guideline emphasizes stopping the sliding scale when it is not needed daily 1.
Target Range and Safety Considerations
The premeal glucose goal for elderly patients is 90–150 mg/dL (5.0–8.3 mmol/L), though this may be adjusted based on overall health and goals of care 1. This is notably more relaxed than targets for younger adults, reflecting the priority of avoiding hypoglycemia in this vulnerable population.
Critical Safety Thresholds
- Avoid hypoglycemia <80 mg/dL (<4.4 mmol/L): If more than 2 fasting values per week fall below this threshold, decrease insulin doses by 2 units 1
- Do not use rapid- or short-acting insulin at bedtime in elderly patients 1
Practical Implementation
When managing an 80-year-old patient:
- Check premeal CBG before each meal
- Apply the simplified sliding scale only when glucose exceeds the thresholds above
- Monitor for patterns: If sliding scale insulin is needed daily, the basal or prandial insulin regimen requires adjustment rather than continued reliance on correction doses 1
- Titrate every 2 weeks based on premeal finger-stick testing, adjusting doses if 50% of values over 2 weeks are above the 90-150 mg/dL goal 1
Important Caveats
Avoid traditional sliding scale-only regimens. While the guideline provides specific thresholds for correction insulin, research demonstrates that sliding scale insulin regimens used as the sole management strategy have no proven benefit, increase hypoglycemia risk, and cause large glucose fluctuations 2. The correction doses should supplement a basal insulin regimen, not replace structured insulin therapy.
The higher thresholds (250 and 350 mg/dL) for elderly patients reflect the shift in priorities toward preventing hypoglycemia and its associated morbidity (falls, cognitive impairment, cardiovascular events) over achieving tight glycemic control 1.